Clinical Trial Update: CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update for a CAR-T cell therapy in relapsed or refractory hematologic malignancies. It is sponsored by Hebei Senlang Biotechnology and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• CAR-T cell therapy

Snippet

Sponsor: Hebei Senlang Biotechnology Inc., Ltd. | Conditions: Leukemia, Lymphoma | Phase 1 | Status: UNKNOWN